Research Summary

I am an academic neuro-oncologist, focused on caring for adult patients with primary brain tumors. In addition to my neurology and neuro-oncology training, I also have a Masters in Public Health (MPH), which I apply to clinical trial development and analysis. I am very active in research areas of novel treatment strategies to improve outcomes for patients with gliomas. I collaborate and serve as the principle investigator on several investigator-initiated, industry-sponsored, and consortia trials. I am involved in the UCSF federal SPORE grant investigating novel ways of investigating the relationship of the immune system with glioma. I also lead our research efforts investigating strategies for improving cognition, quality-of-life, and palliative care for our patients, as well as their caregivers. 

Education

  • Randolph-Macon Woman's College, B.S., 06/2001, Biology 
  • University of Kentucky College of Medicine, 06/2007, M.D. 
  • University of Virginia, Residency, 06/2011, Neurology 
  • Massachusetts General Hospital/Dana Farber Cancer Institute/Brigham and Women's Hospital/Harvard Medical School, Fellowship, 06/2014, Neuro-Oncology 
  • Harvard School of Public Health, 06/2014, MPH 

Honors & Awards

  • 2007
    General Clinical Research Center Medical/Dental Mentorship Award, University of Kentucky College of Medicine
  • 2010
    Chief resident in Neurology, University of Virginia College of Medicine
  • 2012
    K12 training grant recipient, "Training Program in Nervous System Tumors", Massachusetts General Hospital

Selected Publications

  1. Asogwa OA, Dirven L, Walbert T, Armstrong TS, Arons D, van den Bent MJ, Blakeley J, Coomans MB, Brown PD, Bulbeck H, Chang SM, Coens C, Gilbert MR, Grant R, Jalali R, Koekkoek JAF, Panda PK, Leach D, Leeper H, Mendoza T, Nayak L, Oliver K, Reijneveld JC, Le Rhun E, Rubinstein L, Taylor JW, Weller M, Wen PY, Taphoorn MJB. Establishing the content validity of Patient-Reported Outcome measures used in neuro-oncology based on the WHO ICF framework: part of the RANO-PRO initiative. Neuro Oncol. 2025 Apr 28.  View on PubMed
  2. Cannataro VL, Bracci PM, Taylor JW, McCoy L, Rice T, Hansen HM, Heffernan AE, Wiemels J, Wiencke J, Wrensch M, Claus EB. Glioma mutational signatures associated with haloalkane exposure are enriched in firefighters. Cancer. 2025 Mar 15; 131(6):e35732.  View on PubMed
  3. Young JS, Cho NW, Lucas CG, Najem H, Mirchia K, Chen WC, Seo K, Zakimi N, Daggubati V, Casey-Clyde T, Nguyen MP, Chen A, Phillips JJ, Ozawa T, Aghi MK, Taylor JW, DeRisi JL, Bhaduri A, Berger MS, Heimberger AB, Butowski N, Spitzer MH, Raleigh DR. IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma. bioRxiv. 2025 Mar 14.  View on PubMed
  4. Rodriguez Almaraz E, Guerra GA, Al-Adli NN, Young JS, Dada A, Quintana D, Taylor JW, Oberheim Bush NA, Clarke JL, Butowski NA, de Groot J, Pekmezci M, Perry A, Bollen AW, Scheffler AW, Glidden DV, Phillips JJ, Costello JF, Chang EF, Hervey-Jumper S, Berger MS, Francis SS, Chang SM, Solomon DA. Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survival. Neurooncol Adv. 2025 Jan-Dec; 7(1):vdaf024.  View on PubMed
  5. Lucas CG, Al-Adli NN, Young JS, Gupta R, Morshed RA, Wu J, Ravindranathan A, Shai A, Oberheim Bush NA, Taylor JW, de Groot J, Villanueva-Meyer JE, Pekmezci M, Perry A, Bollen AW, Theodosopoulos PV, Aghi MK, Chang EF, Hervey-Jumper SL, Raleigh DR, Molinaro AM, Costello JF, Diaz AA, Clarke JL, Butowski NA, Phillips JJ, Chang SM, Berger MS, Solomon DA. Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025 Jan 12; 27(1):89-105.  View on PubMed
  6. Guerra G, Wendt G, McCoy L, Hansen HM, Kachuri L, Molinaro AM, Rice T, Guan V, Capistrano L, Hsieh A, Kalsi V, Sallee J, Taylor JW, Clarke JL, Almaraz ER, Wiencke JK, Eckel-Passow JE, Jenkins RB, Wrensch M, Francis SS. Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. Neuro Oncol. 2025 Jan 02.  View on PubMed
  7. Darlix A, Preusser M, Hervey-Jumper SL, Shih HA, Mandonnet E, Taylor JW. Who will benefit from vorasidenib? Review of data from the literature and open questions. Neurooncol Pract. 2025 Feb; 12(Suppl 1):i6-i18.  View on PubMed
  8. Guerra G, Wendt G, McCoy L, Hansen HM, Kachuri L, Molinaro AM, Rice T, Guan V, Capistrano L, Hsieh A, Kalsi V, Sallee J, Taylor JW, Clarke JL, Rodriguez Almaraz E, Wiencke JK, Eckel-Passow JE, Jenkins RB, Wrensch M, Francis SS. Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomide. medRxiv. 2024 Oct 10.  View on PubMed
  9. Taylor JW, Warrier G, Hansen HM, McCoy L, Rice T, Guerra G, Francis SS, Clarke JL, Bracci PM, Hadad S, Kelsey KT, Wrensch M, Molinaro AM, Wiencke JK. Oligodendroglioma patient survival is associated with circulating B-cells and age. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae143.  View on PubMed
  10. Crooms RC, Nnemnbeng JF, Taylor JW, Goldstein NE, Vickrey BG, Gorbenko K. "Life…Gets Turned Upside-Down…" Opportunities to Improve Palliative Care for High-Grade Glioma. J Pain Symptom Manage. 2024 Sep; 68(3):272-281.e2.  View on PubMed
  11. Liu J, Jakary A, Villanueva-Meyer JE, Butowski NA, Saloner D, Clarke JL, Taylor JW, Oberheim Bush NA, Chang SM, Xu D, Lupo JM. Automatic Brain Tissue and Lesion Segmentation and Multi-Parametric Mapping of Contrast-Enhancing Gliomas without the Injection of Contrast Agents: A Preliminary Study. Cancers (Basel). 2024 Apr 17; 16(8).  View on PubMed
  12. Crooms RC, Nnemnbeng JF, Taylor JW, Goldstein NE, Gorbenko K, Vickrey BG. Clinician perspectives on integrating neuro-oncology and palliative care for patients with high-grade glioma. Neurooncol Pract. 2024 Aug; 11(4):404-412.  View on PubMed
  13. Röttgering JG, Taylor JW, Brie M, Luks T, Hervey-Jumper SL, Phan S, Bracci PM, Smith E, De Witt Hamer PC, Douw L, Weyer-Jamora C, Klein M. Understanding the association between fatigue and neurocognitive functioning in patients with glioma: A cross-sectional multinational study. Neurooncol Pract. 2024 Jun; 11(3):284-295.  View on PubMed
  14. Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H. A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. Neuro Oncol. 2024 02 02; 26(2):335-347.  View on PubMed
  15. Ranjan S, Leung D, Ghiaseddin AP, Taylor JW, Lobbous M, Dhawan A, Budhu JA, Coffee E, Melnick K, Chowdhary SA, Lu-Emerson C, Kurz SC, Burke JE, Lam K, Patel MP, Dunbar EM, Mohile NA, Peters KB. Practical guidance for direct oral anticoagulant use in the treatment of venous thromboembolism in primary and metastatic brain tumor patients. Cancer. 2024 May 01; 130(9):1577-1589.  View on PubMed
  16. Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2024 Jan; 30(1):302.  View on PubMed
  17. Wiencke JK, Nissen E, Koestler DC, Tamaki SJ, Tamaki CM, Hansen HM, Warrier G, Hadad S, McCoy L, Rice T, Clarke J, Taylor JW, Salas LA, Christensen BC, Kelsey KT, Butler R, Molinaro AM. Enrichment of a neutrophil-like monocyte transcriptional state in glioblastoma myeloid suppressor cells. Res Sq. 2023 Dec 28.  View on PubMed
  18. Hadad S, Gupta R, Oberheim Bush NA, Taylor JW, Villanueva-Meyer JE, Young JS, Wu J, Ravindranathan A, Zhang Y, Warrier G, McCoy L, Shai A, Pekmezci M, Perry A, Bollen AW, Phillips JJ, Braunstein SE, Raleigh DR, Theodosopoulos P, Aghi MK, Chang EF, Hervey-Jumper SL, Costello JF, de Groot J, Butowski NA, Clarke JL, Chang SM, Berger MS, Molinaro AM, Solomon DA. "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. Acta Neuropathol. 2023 12 11; 147(1):3.  View on PubMed
  19. Taylor JW. Neurologic Complications of Conventional Chemotherapy and Radiation Therapy. Continuum (Minneap Minn). 2023 12 01; 29(6):1809-1826.  View on PubMed
  20. Crooms RC, Taylor JW, Jette N, Morgenstern R, Agarwal P, Goldstein NE, Vickrey BG. Palliative care referral across the disease trajectory in high-grade glioma. J Neurooncol. 2023 May; 163(1):249-259.  View on PubMed

Go to UCSF Profiles, powered by CTSI